Vyleesi Cost in Connecticut 2026: Prices, Insurance, Medicaid, and Compounding Options

What Is Bremelanotide and Why Does Cost Vary So Much?

Bremelanotide is the active ingredient in Vyleesi, a melanocortin receptor agonist that the FDA approved on June 21, 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Unlike flibanserin (Addyi), which is taken daily, bremelanotide is dosed as needed, injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity [1].

The price gap between branded Vyleesi and compounded bremelanotide is wide because branded biologics and specialty drugs carry manufacturer pricing that reflects development costs, whereas 503A compounding pharmacies prepare patient-specific formulations at ingredient cost plus dispensing fees. In Connecticut, that gap runs from roughly $1,200 per month for branded Vyleesi down to around $140 per month for compounded bremelanotide, a difference of over $1,000 monthly.

HSDD is defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as persistently or recurrently deficient sexual desire causing marked personal distress [2]. The American College of Obstetricians and Gynecologists (ACOG) recognizes HSDD as a clinical diagnosis warranting treatment in appropriate candidates [3]. Prevalence estimates from population-based surveys suggest roughly 10% of U.S. women meet HSDD criteria at any given time, though rates vary by age group and study methodology [4].

Because HSDD treatment falls under women's sexual health, a category that has historically received less insurance coverage than comparable men's sexual health conditions, the out-of-pocket burden on patients has drawn ongoing policy attention. A 2016 analysis in the Journal of Sexual Medicine estimated that women's sexual dysfunction treatments faced coverage denial rates substantially higher than erectile dysfunction medications, though that disparity has narrowed modestly since Vyleesi's 2019 approval [5].

Vyleesi List Price in Connecticut in 2026

The manufacturer list price for Vyleesi is approximately $1,200 per month in Connecticut. That figure represents the wholesale acquisition cost (WAC) for one auto-injector carton (four 1.75 mg prefilled injectors), which is the standard monthly supply based on the prescribing label's frequency guidance of no more than one dose per 24 hours [1].

Cash prices at Connecticut retail pharmacies track closely to the WAC because Vyleesi lacks generic competition. GoodRx and similar discount aggregators may reduce that price by 5 to 15 percent at specific pharmacies, but savings in that range still leave most patients paying over $1,000 per fill. The absence of generic bremelanotide is a function of patent protection; Palatin Technologies holds composition-of-matter patents that are not expected to expire before the late 2020s [6].

For context, the RECONNECT trial program (two key phase III trials, combined N=1,247) enrolled women aged 22 to 70 with premenopausal HSDD and demonstrated that bremelanotide produced statistically significant improvements in satisfying sexual events per month and in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score compared with placebo at 24 weeks [7]. The fact that the drug reached approval through two rigorous trials contributed to Palatin's pricing rationale, though that rationale does not reduce the financial burden on Connecticut patients who lack insurance coverage.

Patients paying cash in Connecticut should ask their pharmacist to check the 340B price if they receive care at a federally qualified health center (FQHC) or other 340B-covered entity. The 340B program mandates ceiling prices that can be significantly below WAC for covered entities, and Connecticut has an active network of FQHCs including Community Health Center, Inc. and Fair Haven Community Health Care [8].

Connecticut Medicaid Coverage for Vyleesi

Connecticut Medicaid (HUSKY Health) covers bremelanotide with prior authorization for premenopausal women diagnosed with HSDD. The prior authorization (PA) requirement means the prescriber must submit clinical documentation before the state will approve payment. Typical PA criteria for HSDD medications under state Medicaid programs include a confirmed DSM-5 diagnosis, documentation that the distress is not attributable to a co-occurring condition or medication side effect, and sometimes evidence that a trial of non-pharmacologic therapy has been considered [9].

The PA process in Connecticut generally takes 3 to 10 business days for standard review, though urgent review can be requested when clinically justified. Prescribers who are unfamiliar with the PA pathway should reference the HUSKY Health preferred drug list (PDL) and the associated clinical criteria published by the Connecticut Department of Social Services [9].

Connecticut expanded Medicaid under the Affordable Care Act, giving HUSKY Health a broader coverage population than states that did not expand. As of 2025, HUSKY Health covers approximately 900,000 Connecticut residents [10]. Women in that population who meet HSDD diagnostic criteria and satisfy PA requirements should be able to access Vyleesi at little to no cost once approval is granted, because Medicaid cost-sharing for covered drugs is capped at nominal amounts for most enrollees.

If a PA is denied, the prescriber has the right to appeal. Connecticut Medicaid appeals follow a structured process with deadlines defined under state administrative code. A written denial notice must specify the clinical criteria that were not met, giving the prescriber a clear target for the appeal submission [11]. Including a letter of medical necessity with supporting clinical notes from the initial visit tends to strengthen appeals for HSDD medications, which some reviewers still categorize as lifestyle rather than medical treatments despite FDA approval [3].

Commercial Insurance Coverage for Vyleesi in Connecticut

Commercial insurance coverage for Vyleesi in Connecticut varies by plan. Most large employer-sponsored plans administered by Aetna, Cigna, UnitedHealthcare, and Anthem (Elevance Health) include Vyleesi on their specialty tier formularies, typically requiring PA and step therapy documentation [12].

Step therapy requirements most commonly ask the prescriber to document that the patient has tried and had an inadequate response to, or is contraindicated for, flibanserin (Addyi) before approving Vyleesi. This is medically controversial because the two drugs have different mechanisms, different dosing schedules, and different side-effect profiles. Bremelanotide's label carries a warning about transient blood pressure changes and nausea, while flibanserin's label carries a black-box warning about CNS depression and hypotension with alcohol [1] [13]. Treating them as interchangeable first- and second-line agents is not supported by clinical guidelines from the International Society for the Study of Women's Sexual Health (ISSWSH) [14].

The ISSWSH 2019 process-of-care algorithm for HSDD recommends individualized treatment selection based on patient preference, comorbidities, and contraindication profile rather than a one-size-fits-all step sequence [14]. Prescribers can cite that guideline in PA appeals when step therapy criteria require a prior flibanserin trial that is not clinically appropriate for the individual patient.

Connecticut's Insurance Department regulates step therapy and PA practices under state law. Connecticut enacted step-therapy reform legislation that requires insurers to grant exceptions when step therapy is clinically contraindicated or when the patient previously tried the required drug and it failed. Prescribers should document that exception basis clearly in any PA submission [15].

Specialty tier cost-sharing for Vyleesi under commercial plans in Connecticut commonly runs from $150 to $400 per month after deductible, depending on the plan's coinsurance structure. The Palatin Technologies savings card (described in a later section) can offset that cost for eligible patients.

Compounded Bremelanotide in Connecticut: Legality and Cost

Compounded bremelanotide is legal in Connecticut when prepared by a state-licensed 503A pharmacy for a specific patient under a valid prescription from a licensed prescriber. The 503A pathway, established under Section 503A of the Federal Food, Drug, and Cosmetic Act, allows traditional compounding pharmacies to prepare patient-specific formulations that are not commercially available or are not appropriate for a given patient in their commercial form [16].

The FDA does not consider bremelanotide a "difficult to compound" substance, and it does not appear on the FDA's current list of drugs that may not be compounded under 503A [16]. Connecticut's Department of Consumer Protection, Pharmacy Unit, licenses and inspects compounding pharmacies operating within the state. Prescriptions for compounded bremelanotide must be issued for an identified individual patient; bulk compounding for office stock is not permitted under 503A [16].

The cost difference is significant. Compounded bremelanotide from a licensed Connecticut 503A pharmacy typically runs approximately $140 per month for a supply equivalent to the branded monthly dose volume. That price reflects the cost of pharmaceutical-grade active pharmaceutical ingredient (API), the compounding fee, and dispensing overhead, without the brand premium embedded in Vyleesi's $1,200 list price.

Patients and prescribers should verify that any compounding pharmacy holds a current Connecticut pharmacy license and, ideally, a Pharmacy Compounding Accreditation Board (PCAB) accreditation, which signals adherence to USP <797> and USP <800> sterile compounding standards [17]. Subcutaneous injectables fall under sterile compounding requirements, so facility quality matters directly for patient safety.

One practical limitation: commercial insurance plans and Connecticut Medicaid do not cover compounded bremelanotide. Coverage pathways described above apply only to FDA-approved branded Vyleesi. Patients choosing compounded bremelanotide pay out of pocket, but at roughly $140 per month, the cash price is substantially lower than the post-deductible cost-sharing on branded Vyleesi under many commercial plans.

Telehealth Prescribing of Vyleesi in Connecticut

Vyleesi can be prescribed via telehealth in Connecticut. The state's telehealth statute permits licensed prescribers to evaluate patients and issue prescriptions through synchronous video visits, provided the standard of care for the relevant condition can be met through that modality [18].

HSDD diagnosis relies primarily on clinical history, validated questionnaires such as the FSDS-DAO and the Female Sexual Function Index (FSFI), and the exclusion of organic or medication-related causes. A thorough synchronous video visit with a trained clinician can address those elements. Pelvic examination is not required for an HSDD diagnosis based on DSM-5 criteria, though the prescriber should document that a recent general physical examination has been performed and that relevant laboratory work (thyroid function, prolactin, testosterone where indicated) has been reviewed [14].

Connecticut does not require an in-person visit before a telehealth prescription can be issued for Vyleesi, unlike controlled substances where the Ryan Haight Act and DEA registration requirements apply. Bremelanotide is not a controlled substance [1], so the telehealth pathway is straightforward from a regulatory standpoint.

HealthRX connects Connecticut patients with board-certified clinicians via telehealth for HSDD evaluation. After a clinical consultation, eligible patients can receive a Vyleesi prescription or a compounded bremelanotide prescription sent directly to a Connecticut pharmacy or mail-order pharmacy of their choice.

The Palatin Technologies Savings Card in Connecticut

Palatin Technologies offers a copay savings program for commercially insured patients filling branded Vyleesi at participating pharmacies. Eligible patients may pay as little as $0 per fill, with the savings card covering the gap between insurance payment and the patient's copay or coinsurance up to a defined annual maximum [19].

Key eligibility restrictions apply. The savings card is not valid for patients covered by federal or state government insurance programs, including Connecticut Medicaid (HUSKY Health), Medicare, or TRICARE. Patients with commercial insurance from employer-sponsored or individual market plans are generally eligible [19].

To use the card, patients or prescribers enroll through the Vyleesi manufacturer website, receive a card or electronic BIN/PCN number, and present it at the pharmacy alongside their insurance card at time of dispensing. The pharmacy processes the insurance claim first and then applies the savings card as a secondary discount.

Connecticut patients who are uninsured and do not qualify for Medicaid should contact Palatin's patient assistance program separately, as manufacturer patient assistance programs (PAPs) can provide branded medication at no cost to patients who meet income criteria, typically at or below 400% of the federal poverty level [19]. Given that compounded bremelanotide at $140 per month is already substantially cheaper for cash-pay patients, the PAP is most relevant for patients who specifically need the branded auto-injector device or who are uncomfortable with compounded formulations.

Clinical Evidence Supporting Bremelanotide Use

The approval of Vyleesi rests primarily on the RECONNECT trial program, which comprised two identical phase III randomized controlled trials published in Obstetrics and Gynecology in 2019. The combined intent-to-treat population was 1,247 premenopausal women with acquired, generalized HSDD [7].

In RECONNECT, bremelanotide 1.75 mg produced a statistically significant increase in the number of satisfying sexual events per month compared with placebo over 24 weeks of as-needed use (P<0.001 for the FSDS-DAO desire domain score) [7]. The proportion of women who reported a clinically meaningful improvement in sexual desire was significantly higher in the bremelanotide group than the placebo group. Nausea was the most common adverse event, reported in approximately 40% of bremelanotide recipients versus 1% of placebo recipients, and most nausea episodes resolved within 12 hours [7].

The FDA's medical review noted that the magnitude of benefit, while statistically significant, was modest in absolute terms. Mean change from baseline in the FSDS-DAO desire domain score was approximately 0.3 points greater in the bremelanotide group than placebo on a scale of 0 to 4 [1]. The FDA's approval reflected the judgment that even modest improvements in desire and reductions in distress represent meaningful clinical benefit for women with HSDD, a condition that lacks abundant treatment options [1].

Blood pressure effects merit prescriber attention. Bremelanotide produces a transient mean increase in systolic blood pressure of approximately 2 mmHg and a decrease in heart rate of approximately 4 bpm in the hour after injection [1]. The label contraindicates bremelanotide in patients with known cardiovascular disease. Prescribers should assess baseline cardiovascular risk before initiating therapy, including blood pressure measurement and relevant cardiac history [1].

A 2021 review in the Journal of Sexual Medicine examined real-world adherence to bremelanotide and found that about 30% of patients discontinued within the first three months, primarily due to nausea, highlighting the practical importance of counseling patients about side-effect management strategies before the first injection [20].

Comparing Your Cost Options in Connecticut: A Decision Framework

Connecticut patients have four main cost pathways for bremelanotide access, each with different eligibility requirements and monthly outlays.

Branded Vyleesi with commercial insurance and savings card: Monthly out-of-pocket can reach $0 for eligible commercially insured patients using the Palatin savings card. Requires PA in most plans and may require step therapy documentation. Best for patients with employer-sponsored insurance whose plan covers Vyleesi on formulary.

Connecticut Medicaid (HUSKY Health): Covered with PA for eligible premenopausal women. Cost-sharing is nominal once approved. Requires DSM-5 diagnosis documentation and satisfying PA clinical criteria. Not available for compounded bremelanotide.

Compounded bremelanotide via 503A pharmacy: Approximately $140 per month cash pay. Legal in Connecticut for patient-specific prescriptions. Not covered by insurance. Best for patients who are uninsured, underinsured, or whose commercial plan's post-deductible cost-sharing on branded Vyleesi exceeds $140 per month.

Branded Vyleesi cash pay without savings card: Approximately $1,200 per month. Rarely the best option given the other pathways above; relevant only if the patient is ineligible for all other options or requires the branded auto-injector device specifically.

Patients who receive care at a 340B-covered entity (FQHC, Ryan White clinic, or other qualifying site) may access branded Vyleesi at a 340B ceiling price that is meaningfully below WAC, even without insurance [8]. That pathway is worth exploring before defaulting to cash pay.

The ISSWSH process-of-care algorithm recommends that clinicians document the full range of treatment options, their costs, and patient preferences before initiating pharmacologic therapy for HSDD [14]. Reviewing these four pathways with the patient at the time of diagnosis allows shared decision-making that accounts for both clinical appropriateness and financial feasibility.